BACKGROUND: The receptor tyrosine kinase Axl has been reported to be overexpressed in a variety of human cancers. Although previous studies have identified the role of Axl in the transformation, proliferation, survival, and invasion in cancers, the expression and functions of Axl in pancreatic cancer have not been studied in detail. METHODS: The expression of Axl protein in 12 pancreatic cancer cell lines and 54 patient samples of stage II pancreatic ductal adenocarcinoma (PDA) and their paired non-neoplastic pancreatic tissue samples were examined. Using univariate and multivariate analysis, Axl expression was correlated with survival and other clinicopathologic features. To examine Axl functions in PDA, the effects of Axl knockdown on the invasion ability and radiation-induced apoptosis in PDA cell lines were measured. RESULTS: Axl was overexpressed in 38 of 54 (70%) stage II PDA samples and 9 of 12 (75%) PDA cell lines. Axl overexpression was associated with higher frequencies of distant metastasis and poor overall and recurrence-free survivals (P = .03 and P = .04, respectively) independent of tumor size and stage or lymph node status in patients with stage II PDA. Knockdown of Axl expression in PDA cells abolished Gas6-mediated Akt activation, decreased invasion, and increased radiation-induced PARP cleavage and the percentage of apoptosis. CONCLUSIONS: This study showed that Gas6 and Axl are frequently overexpressed in PDA cells and are associated with a poor prognosis in patients with stage II PDA. Axl promotes the invasion and survival of PDA cells. Therefore, targeting the Axl signaling pathway may represent a new approach to the treatment of PDA.
BACKGROUND: The receptor tyrosine kinaseAxl has been reported to be overexpressed in a variety of humancancers. Although previous studies have identified the role of Axl in the transformation, proliferation, survival, and invasion in cancers, the expression and functions of Axl in pancreatic cancer have not been studied in detail. METHODS: The expression of Axl protein in 12 pancreatic cancer cell lines and 54 patient samples of stage II pancreatic ductal adenocarcinoma (PDA) and their paired non-neoplastic pancreatic tissue samples were examined. Using univariate and multivariate analysis, Axl expression was correlated with survival and other clinicopathologic features. To examine Axl functions in PDA, the effects of Axl knockdown on the invasion ability and radiation-induced apoptosis in PDA cell lines were measured. RESULTS:Axl was overexpressed in 38 of 54 (70%) stage II PDA samples and 9 of 12 (75%) PDA cell lines. Axl overexpression was associated with higher frequencies of distant metastasis and poor overall and recurrence-free survivals (P = .03 and P = .04, respectively) independent of tumor size and stage or lymph node status in patients with stage II PDA. Knockdown of Axl expression in PDA cells abolished Gas6-mediated Akt activation, decreased invasion, and increased radiation-induced PARP cleavage and the percentage of apoptosis. CONCLUSIONS: This study showed that Gas6 and Axl are frequently overexpressed in PDA cells and are associated with a poor prognosis in patients with stage II PDA. Axl promotes the invasion and survival of PDA cells. Therefore, targeting the Axl signaling pathway may represent a new approach to the treatment of PDA.
Authors: Sacha J Holland; Mark J Powell; Christian Franci; Emily W Chan; Annabelle M Friera; Robert E Atchison; John McLaughlin; Susan E Swift; Erlina S Pali; George Yam; Stephen Wong; Joe Lasaga; Mary R Shen; Simon Yu; Weiduan Xu; Yasumichi Hitoshi; Jakob Bogenberger; Jacques E Nör; Donald G Payan; James B Lorens Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich Journal: Proc Natl Acad Sci U S A Date: 2006-04-03 Impact factor: 11.205
Authors: Benjamin I Chung; S Bruce Malkowicz; Trang B Nguyen; John A Libertino; Terence W McGarvey Journal: DNA Cell Biol Date: 2003-08 Impact factor: 3.311
Authors: R J Craven; L H Xu; T M Weiner; Y W Fridell; G A Dent; S Srivastava; B Varnum; E T Liu; W G Cance Journal: Int J Cancer Date: 1995-03-16 Impact factor: 7.396
Authors: Kathleen F Ludwig; Wenting Du; Noah B Sorrelle; Katarzyna Wnuk-Lipinska; Mary Topalovski; Jason E Toombs; Victoria H Cruz; Shinichi Yabuuchi; N V Rajeshkumar; Anirban Maitra; James B Lorens; Rolf A Brekken Journal: Cancer Res Date: 2017-11-27 Impact factor: 12.701
Authors: Kenji Yumoto; Matthew R Eber; Janice E Berry; Russell S Taichman; Yusuke Shiozawa Journal: Clin Cancer Res Date: 2014-04-22 Impact factor: 12.531
Authors: Nellie K McDaniel; Christopher T Cummings; Mari Iida; Justus Hülse; Hannah E Pearson; Eleana Vasileiadi; Rebecca E Parker; Rachel A Orbuch; Olivia J Ondracek; Noah B Welke; Grace H Kang; Kurtis D Davies; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Paul M Harari; Randall J Kimple; Deborah DeRyckere; Douglas K Graham; Deric L Wheeler Journal: Mol Cancer Ther Date: 2018-08-09 Impact factor: 6.261
Authors: Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong Journal: Cancer Metastasis Rev Date: 2014-09 Impact factor: 9.264
Authors: Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; John P Coan; Hannah E Pearson; Harsh Bahrar; Tyler L Fowler; Bryan P Bednarz; Sandeep Saha; David Yang; Parkash S Gill; Mark W Lingen; Vassiliki Saloura; Victoria M Villaflor; Ravi Salgia; Randall J Kimple; Deric L Wheeler Journal: Clin Cancer Res Date: 2015-03-12 Impact factor: 12.531